Establishing a diagnosis of sepsis InfectID™ as the new standard of care
BRISBANE, Australia, December 5, 2024 /PRNewswire/ — Microbio Ltd, the Australian pathogen diagnostics company specializing in innovative molecular diagnostic solutions, today announced the appointment of Paul Perreault as a strategic advisor.
Mr. Perreault is the former CEO of CSL and considered a preeminent global leader in biotechnology. He served as Chief Executive Officer and Chief Executive Officer of CSL Limited from 2013 to 2023, leading the organization to become the fifth largest biotechnology company in the world, bringing life-saving medicines to people in more than 100 countries.
Microbio markets InfectID™ BSI (Bloodstream Infection) as a new standard in sepsis diagnosis. InfectID™-BSI currently carries the CE mark and is authorized for sale in Europe, United KingdomAnd Indiawith an advanced regulatory program underway for FDA and TGA approval, paving the way for global market expansion in the years to come.
The InfectID™-BSI diagnostic test provides actionable information to clinicians, enabling them to provide targeted antimicrobial therapy, thereby improving patient outcomes and reducing the emergence of antimicrobial-resistant organisms.
The test detects 26 pathogens associated with more than 94% of sepsis cases in less than 3 hours.
Sepsis is a life-threatening illness caused by the body’s reaction to a blood infection. The only effective treatment is rapid administration of antimicrobials to eliminate the pathogen causing the infection. For every hour of delay in administering appropriate antimicrobial therapy, mortality rates increase by 7.6%.1highlighting the urgent need for rapid diagnosis. The current gold standard method involves a slow, multi-step process of blood culture and identification. This approach takes 11 hours to 21 hours for bacterial species and 48 hours for Candida species and has limited sensitivity.
Microbio’s InfectID™ is therefore considered a revolutionary tool in improving outcomes for sepsis patients through earlier detection.
This latest appointment strengthens Microbio’s management team and advisors in supporting the rapid commercialization and expanded market access of InfectID™.
With over 40 years of experience in the global healthcare industry, Mr. Perreault has held senior management positions at CSL, Wyeth, Centeon, Aventis Bioservices and Aventis Behring. He previously served on the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Wall Street Journal CEO Council, the Penn State Provost Global Advisory Board, and the Plasma Protein Therapeutics Association Global Board.
Commenting on his appointment, Mr. Perreault said: “Microbio is an exciting biotechnology company poised to positively disrupt the devastating impact of sepsis on patients with a diagnostic test that can more quickly detect the majority of sepsis-causing pathogens, enabling clinical intervention and much earlier treatment to ultimately secure lives and improve patient outcomes. I am pleased to work with a company at the forefront of innovation in this critical area of healthcare.
Offer from the general director of Microbio, Mr. Colin Keating said: “We have a growing number of clinical and key opinion leaders working with us to bring InfectID™ to market as our clinical data continues to support the profound benefits of our sepsis diagnostics. We welcome Paul to our Advisory Board and have the opportunity to leverage his exceptional leadership and capabilities to support our ongoing global expansion.
[End]
Additional information https://microbio.com.au/
Show original content:https://www.prnewswire.com/apac/news-releases/former-csl-ceo-paul-perreault-appointed-strategic-adviser-to-microbio-302321848.html
SOURCE Microbio
